ZYN002 - transdermal gel ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 206 | Fragile X syndrome | 1 |
206. Fragile X syndrome
Clinical trials : 108 / Drugs : 91 - (DrugBank : 36) / Drug target genes : 52 - Drug target pathways : 77
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04977986 (ClinicalTrials.gov) | September 13, 2021 | 20/7/2021 | Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome | A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT | Fragile X Syndrome | Drug: ZYN002 - transdermal gel;Drug: Placebo | Zynerba Pharmaceuticals, Inc. | NULL | Recruiting | 3 Years | 23 Years | All | 204 | Phase 3 | United States;Australia;Ireland;United Kingdom |